312 related articles for article (PubMed ID: 9628601)
21. Intravesical valrubicin in the treatment of carcinoma in situ of the bladder.
Kuznetsov DD; Alsikafi NF; O'Connor RC; Steinberg GD
Expert Opin Pharmacother; 2001 Jun; 2(6):1009-13. PubMed ID: 11585003
[TBL] [Abstract][Full Text] [Related]
22. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors.
Palou J; Laguna P; Millán-Rodríguez F; Hall RR; Salvador-Bayarri J; Vicente-Rodríguez J
J Urol; 2001 May; 165(5):1488-91. PubMed ID: 11342902
[TBL] [Abstract][Full Text] [Related]
23. Laser photodynamic therapy for bladder cancer.
Benson RC
Mayo Clin Proc; 1986 Nov; 61(11):859-64. PubMed ID: 2945058
[TBL] [Abstract][Full Text] [Related]
24. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy.
Barlow L; McKiernan J; Sawczuk I; Benson M
BJU Int; 2009 Oct; 104(8):1098-102. PubMed ID: 19389012
[TBL] [Abstract][Full Text] [Related]
25. Pilot study on light dosimetry variables for photodynamic therapy of Barrett's esophagus with high-grade dysplasia.
Gill KR; Wolfsen HC; Preyer NW; Scott MV; Gross SA; Wallace MB; Jones LR
Clin Cancer Res; 2009 Mar; 15(5):1830-6. PubMed ID: 19240171
[TBL] [Abstract][Full Text] [Related]
26. Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation.
Ovesen H; Horn T; Steven K
J Urol; 1997 May; 157(5):1655-9. PubMed ID: 9112499
[TBL] [Abstract][Full Text] [Related]
27. Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation.
Nieder AM; Simon MA; Kim SS; Manoharan M; Soloway MS
Urology; 2006 Apr; 67(4):737-41. PubMed ID: 16618564
[TBL] [Abstract][Full Text] [Related]
28. Long-term survival of patients treated with photodynamic therapy for carcinoma in situ and early non-small-cell lung carcinoma.
Corti L; Toniolo L; Boso C; Colaut F; Fiore D; Muzzio PC; Koukourakis MI; Mazzarotto R; Pignataro M; Loreggian L; Sotti G
Lasers Surg Med; 2007 Jun; 39(5):394-402. PubMed ID: 17565719
[TBL] [Abstract][Full Text] [Related]
29. Long-term results of whole bladder wall photodynamic therapy for carcinoma in situ of the bladder.
D'Hallewin MA; Baert L
Urology; 1995 May; 45(5):763-7. PubMed ID: 7747371
[TBL] [Abstract][Full Text] [Related]
30. Management of high-risk non-muscle invasive bladder cancer.
Brausi M; Olaru V
Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
[TBL] [Abstract][Full Text] [Related]
31. Photodynamic therapy with hematoporphyrin derivative in the treatment of superficial transitional-cell carcinoma of the bladder.
Prout GR; Lin CW; Benson R; Nseyo UO; Daly JJ; Griffin PP; Kinsey J; Tian ME; Lao YH; Mian YZ
N Engl J Med; 1987 Nov; 317(20):1251-5. PubMed ID: 2959863
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group.
Ignatoff JM; Chen YH; Greenberg RE; Pow-Sang JM; Messing EM; Wilding G
Urol Oncol; 2009; 27(5):496-501. PubMed ID: 18639470
[TBL] [Abstract][Full Text] [Related]
33. Conservative treatment of high grade superficial bladder tumours.
Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
[TBL] [Abstract][Full Text] [Related]
34. Long-term effects of bacille Calmette-Guérin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract.
Hayashida Y; Nomata K; Noguchi M; Eguchi J; Koga S; Yamashita S; Hayashi M; Kanatake H
Urology; 2004 Jun; 63(6):1084-8. PubMed ID: 15183955
[TBL] [Abstract][Full Text] [Related]
35. Photodynamic therapy for head and neck dysplasia and cancer.
Rigual NR; Thankappan K; Cooper M; Sullivan MA; Dougherty T; Popat SR; Loree TR; Biel MA; Henderson B
Arch Otolaryngol Head Neck Surg; 2009 Aug; 135(8):784-8. PubMed ID: 19687399
[TBL] [Abstract][Full Text] [Related]
36. [Prophylactic effect of inductive intravesical instillation of Bacillus Calmette-Guerin on postoperative recurrence of bladder cancer].
Yi SH; Ye G; Wang XW; Jin HS; Zhang YN; Yan ZL
Ai Zheng; 2008 Nov; 27(11):1208-11. PubMed ID: 19000455
[TBL] [Abstract][Full Text] [Related]
37. Integral laser photodynamic treatment of refractory multifocal bladder tumors.
Naito K; Hisazumi H; Uchibayashi T; Amano T; Hirata A; Komatsu K; Ishida T; Miyoshi N
J Urol; 1991 Dec; 146(6):1541-5. PubMed ID: 1942336
[TBL] [Abstract][Full Text] [Related]
38. Treatment outcome of Photofrin-based photodynamic therapy for T1 and T2 oral squamous cell carcinoma and dysplasia.
Ikeda H; Tobita T; Ohba S; Uehara M; Asahina I
Photodiagnosis Photodyn Ther; 2013 Sep; 10(3):229-35. PubMed ID: 23993848
[TBL] [Abstract][Full Text] [Related]
39. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR
Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562
[TBL] [Abstract][Full Text] [Related]
40. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed.
O'Donnell MA; Krohn J; DeWolf WC
J Urol; 2001 Oct; 166(4):1300-4, discussion 1304-5. PubMed ID: 11547062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
